NBIX vs. RGEN: Neurocrine Biosciences vs. Repligen Stock Comparison
How do Neurocrine Biosciences (NBIX) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Neurocrine Biosciences (NBIX) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NBIX is classified in Biotechnology while RGEN is classified in Life Sciences Tools & Services.
| Profile Item | NBIX | RGEN |
|---|---|---|
| Name | Neurocrine Biosciences, Inc. | Repligen Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 16.66 billion USD | 11.09 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 23, 1996 | April 29, 1986 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | NBIX | RGEN |
|---|---|---|
| Total Return (1Y) | 9.40% | 23.28% |
| Total Return (3Y, Annualized) | 14.12% | 6.20% |
| Total Return (5Y, Annualized) | 12.61% | -8.41% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | NBIX | RGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 35.05% | 46.73% |
| Beta (5Y) | 0.29 | 1.11 |
| Max Drawdown (5Y) | -42.89% | -64.67% |
| Avg. Volume (3M) | 1.31M | 1.18M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | NBIX | RGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.15 | 0.41 |
| Sortino Ratio (1Y) | 0.22 | 0.60 |
Profitability
ROE (TTM)
Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Neurocrine Biosciences (NBIX) reports 20.42%, ranking against industry peers normally.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.42%
- Max
- 109.18%
- NBIX
- 20.42%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.57%
- Max
- 109.18%
- Q3
- 6.23%
- RGEN
- -0.57%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Neurocrine Biosciences (NBIX) reports 18.98%, ranking against industry peers normally.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.98%
- NBIX
- 18.98%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-1.47%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- RGEN
- -1.47%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Neurocrine Biosciences (NBIX) at 31.98% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.98%
- Max
- 83.12%
- NBIX
- 31.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.19%
- Max
- 83.12%
- Q3
- 14.77%
- RGEN
- 6.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | NBIX | RGEN |
|---|---|---|
| ROE (TTM) | 20.42% | -0.57% |
| ROA (TTM) | 12.45% | 1.40% |
| Net Margin (TTM) | 18.98% | -1.47% |
| Operating Margin (TTM) | 31.98% | 6.19% |
| Gross Margin (TTM) | 64.67% | 53.77% |
Growth
Revenue Growth
Both Neurocrine Biosciences (NBIX) at 21.45% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Neurocrine Biosciences (NBIX) reports EPS growth of 41.95%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.
Growth Metrics
| Metric | NBIX | RGEN |
|---|---|---|
| Revenue Growth (YoY) | 21.45% | 16.36% |
| Revenue Growth (3Y CAGR) | 24.32% | -2.70% |
| EPS Growth (YoY) | 41.95% | -- |
| EPS Growth (3Y CAGR) | 44.12% | -35.73% |
Financial Strength
Current Ratio (MRQ)
Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while Neurocrine Biosciences (NBIX) at 2.04 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NBIX.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.04
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- NBIX
- 2.04
- Min
- 0.10
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88
- Max
- 25.13
- Q3
- 12.13
- RGEN
- 9.88
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Neurocrine Biosciences (NBIX) at 0.12 and Repligen (RGEN) at 0.33 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.12
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NBIX
- 0.12
- Q1
- 0.02
- Min
- 0.00
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.33
- Max
- 1.42
- Q3
- 0.65
- RGEN
- 0.33
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | NBIX | RGEN |
|---|---|---|
| Current Ratio (MRQ) | 2.04 | 9.88 |
| Debt / Equity (MRQ) | 0.12 | 0.33 |
| Net Debt / EBITDA | -0.27 | -1.19 |
Dividends
Dividend Yield (TTM)
Neither Neurocrine Biosciences (NBIX) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Neurocrine Biosciences (NBIX) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | NBIX | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Neurocrine Biosciences (NBIX) trades at 24.43 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.43
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- NBIX
- 24.43
- Q1
- 13.30
- Min
- 0.07
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RGEN
- --
P/S Ratio (TTM)
On P/S ratio, both Neurocrine Biosciences (NBIX) at 4.50 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- NBIX
- 4.50
- Q1
- 3.01
- Min
- 0.01
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.77
- Max
- 58.18
- Q3
- 25.77
- RGEN
- 13.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Neurocrine Biosciences (NBIX) at 4.30 and Repligen (RGEN) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.30
- Max
- 13.53
- Q3
- 6.54
- NBIX
- 4.30
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- RGEN
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | NBIX | RGEN |
|---|---|---|
| P/E Ratio (TTM) | 24.43 | -- |
| P/S Ratio (TTM) | 4.50 | 13.77 |
| P/B Ratio (MRQ) | 4.30 | 4.70 |
| Free Cash Flow Yield (TTM) | 6.11% | 1.01% |